MAIA Biotechnology (NYSEAMERICAN:MAIA) Announces Earnings Results

MAIA Biotechnology (NYSEAMERICAN:MAIA) announced its earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.05, FiscalAI reports.

MAIA Biotechnology Price Performance

Shares of MAIA stock traded up $0.04 during trading hours on Wednesday, hitting $1.48. The company had a trading volume of 171,853 shares, compared to its average volume of 1,050,315. The company’s fifty day moving average is $1.93 and its 200 day moving average is $1.58. MAIA Biotechnology has a fifty-two week low of $0.87 and a fifty-two week high of $3.19. The stock has a market capitalization of $57.22 million, a PE ratio of -2.14 and a beta of -0.04.

Institutional Trading of MAIA Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of MAIA Biotechnology by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after buying an additional 25,684 shares during the period. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology in the 4th quarter valued at $120,000. Finally, Marshall Wace LLP purchased a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at $29,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.